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Case Report

A 54 year-old male with a past medical history of cholangiocarcinoma and portal vein thrombosis was admitted to an outside
hospital with right-sided abdominal pain, leukocytosis and
hyperbilirubinemia. Prior to admission, he received 3 cycles of
gemcitabine however his tumor had increased in size leading to
development of obstructive jaundice. At the hospital, his pain was
attributed to hepatomegaly and biliary obstruction secondary to
tumor size. He was started on Zosyn for presumed diagnosis
of pneumonia and leukocytosis. He was then transferred to
Thomas Jefferson Hospital for a second opinion regarding his
malignancy.
Upon transfer, patient noted right upper quadrant abdominal
pain that he described as constant and dull. He also reported
fatigue and weight loss over last few months. He denied nausea,
vomiting, diarrhea or any change in his bowel movements.
On arrival, his vital signs were stable. Physical exam was
significant for jaundice, distended abdomen and right upper
quadrant tenderness. He also had significant peripheral edema
up to his groin.
Laboratory studies revealed white blood count (WBC) of
24,500/mL, hemoglobin of 8.5 g/dL, and platelets of 416,000/mL.
His sodium was 128 mmol/L and creatinine was 0.6 g/dL. His
total bilirubin was 21.2 mg/dL and alkaline phosphatase was 320
IU/L. His INR was slightly elevated at 1.31.
The patient underwent endoscopic retrograde pancreatography
(ERCP). He was found to have an occlusive common hepatic
duct stricture secondary to a tumor. A plastic stent was
successfully deployed. Seven days after the initial ERCP, patient
became febrile, tachycardic and complained of worsening right
upper quadrant pain. Repeat ERCP revealed purulent debris in
the stent and a strictured left hepatic duct. Two metal stents were
successfully placed leading to decreased in bilirubin. Within 24
hours, the patient’s blood cultures speciated Stenotrophomonas
maltophilia. He was started on intravenous trimethoprimsulfamethoxazole (TMP-SMX). Once patient’s bacterimia
cleared, he was discharged home with hospice services.

Discussion

In the last twenty years, Stenotrophomonas maltophilia has
been increasingly found as an important cause of infection
in hospitalized patients. This hydrophilic organism has been
known by multiple names. It was originally called Bacterium
bookeri when first isolated in 1943 and considered to be a
member of the genus Pseudomonas. It was then classified as
part of the Xanthomonas genus in 1983 until finally reclassified
as Stenotrophomonas in 1993. Although not considered to be
a highly virulent organism, S. maltophilia can cause serious
infections in both immunosuppressed and immunocompetent patients. It is most commonly found in aquatic or

humid environments including drinking water supplies, soil
and on plants. In health care facilities the organism has been
isolated from medical devices, vacuum blood collection tubes,
disinfectant and sterile water.1
Most infections do occur in severely immunocompromised
patients particularly those with cancer and prolonged
neutropenia. Risk factors for infection with S. maltophilia
include extended hospitalization in critical care units, prolonged
mechanical ventilation, presence of tracheostomy, indwelling
devices such as intravascular catheters and endotracheal tubes,
and exposure to broad-spectrum antibiotics. Most S. maltophilia
bacteremias are related to infected in-dwelling catheters. These
infections are usually easily treated with removal of the infected
catheter and antibiotic therapy. In patients with non-catheter
related S. maltophilia, bacteremia treatment failure rates and
infection associated mortality are high.2 In patients with cancer,
risk factors associated with poor outcome include prolonged
neutropenia, bacteremic pneumonia, shock syndrome,
thrombocytopenia and inappropriate initial antibiotic choice.2
The respiratory tract is the most common site of S. maltophilia
infection however it has been found to be the cause of
skin infections, endocarditis, urinary tract infections and
hepatobiliary infections. There have been five reports in the
literature of biliary sepsis secondary to S. maltophilia. All of
these cases occurred in patients with hepatobiliary malignancy
complicated by biliary tract obstruction. Each of these patients
had undergone biliary tract instrumentation prior to developing
S. maltophilia bacteremia.3,4,5 The organism was recovered from
blood in three cases and from bile in the remaining two cases.
All of the patients were treated with antibiotics, four out of
five patients described made a full recovery, the fifth patient
died. The four patients who survived underwent interventional
procedures in addition to receiving antibiotics.
Choosing appropriate antibiotic therapy for S. maltophilia
infections can be difficult and initiation of inappropriate
antimicrobial therapy has been linked to poor outcome.
Although trimethoprim-sulfamethoxazole (TMP-SMX) has
the strongest in vitro activity against S. maltophilia, increasing
resistance rates have been reported in the literature. Despite
these reports, TMP-SMX is still considered the drug of choice
against this organism.2 It has even been suggested that patients
who have serious S. maltophilia infections and are allergic to
sulfa drugs should undergo desensitization in order to be treated
appropriately.4 Other classes of antibiotics such as aminoglycosides and quinolones are not as effective against S. maltophilia.
S. maltophilia, although not considered an aggressive pathogen,
remains an important cause of morbidity and mortality among
immunosuppressed patients. Patients with cancer particularly
those with prolonged neutropenia continue to be at risk of
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infection with this organism. When S. maltophilia infection is
suspected it is important to obtain sensitivity and susceptibility
data and to institute treatment with TMP-SMX when possible.
This organism commonly causes respiratory and catheterrelated infections, however there are rare reports of urinary and
hepatobiliary infections in the literature. When a patient with
hepatobiliary malignancy and biliary tract obstruction presents
with cholangitis or biliary sepsis infection, S. maltophilia should
be considered in the differential of possible pathogens.3
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